Altogether, when administering GLP-1RA plus SGLT2i combination therapy, it is important to adopt an individualized approach to therapy taking into account individual preferences, costs and coverage, toxicity profile, consideration of kidney function and glucose-lowering efficacy, desire for weight loss, and comorbidities
Lower HRV is probably indicative of more SNS activity (in most cases), but we can more confidently state that fluctuations in HRV are more representative of fluctuations in PNS activity (i.e., vagal withdrawal or vagal dominance
R.HenryR
It is able to activate both the GcgR and the GLP-1R but with much reduced potency relative to the native ligands
Nanomedical Drug Delivery for Neurodegenerative Diseases: Academic Press
Thyroid hormone controls the hepatic conversion of -butyrobetaine to carnitine in rats and also increases carnitine bioavailability [26]